Dose-dependent inhibition of GCPII to prevent and treat cognitive impairment in the EAE model of multiple sclerosis
Authors:
- 1 March 2016
- journal article
- Published by Elsevier in Brain Research
- Vol. 1635, 105-112
Abstract
No abstract availableKeywords
Funding Information
- National Multiple Sclerosis Society (AIK)
- NIH (RO1CA161056 (BSS))
- Bruce and Deborah Downey and Mulligans Fore MS
This publication has 30 references indexed in Scilit:
- NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxiaBrain Research, 2013
- NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition testEuropean Journal of Pharmacology, 2013
- Treatment of cognitive impairment in multiple sclerosis: position paperJournal of Neurology, 2012
- Proton MR Spectroscopy–Detectable Major Neurotransmitters of the Brain: Biology and Possible Clinical ApplicationsAmerican Journal of Neuroradiology, 2011
- Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBIBrain Research, 2011
- Lower brain glutamate is associated with cognitive deficits in HIV patients: A new mechanism for HIV‐associated neurocognitive disorderJournal of Magnetic Resonance Imaging, 2010
- Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up studyMultiple Sclerosis Journal, 2010
- Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosisMultiple Sclerosis Journal, 2007
- Identification of the N‐glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activityProtein Science, 2004
- N-acetylated-α-linked-acidic dipeptidase inhibitor has a neuroprotective effect on mouse retinal ganglion cells after pressure-induced ischemiaNeuroscience Letters, 2000